RxDoctor Payments DataLook up a doctor →

John Hill, MD

Family Medicine · Deland, FLNPI 1558380444

Payments from drug & device makers

$6,760,249in general payments, 2019–2025

Across 1,861 payments — averaging $3632.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1.4M
  • UCB SA$1.3M
  • Novartis$772K
  • Regeneron$633K
  • Merck$442K
  • Roche Molecular Systems, Inc.$437K
  • plus $1.8M from 54 others
$61,119in research payments, 2019–2025

Across 4 payments — averaging $15,280 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Valneva Austria GmbH$56K
  • Eli Lilly$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.617$1,386,821
UCB SA5$1,303,694
Novartis46$772,208
Regeneron34$633,360
Merck16$441,710
Roche Molecular Systems, Inc.15$437,498
Valneva Austria GmbH4$372,824
Eli Lilly10$326,120
Pfizer90$258,454
Roche Diagnostics Operations, Inc.13$186,857
Sanofi US Services Inc.19$174,727
BD4$77,540
Lumos Diagnostics, Inc.1$61,600
Intercept Pharmaceuticals, Inc.5$59,132
Boehringer Ingelheim50$56,020
AstraZeneca71$55,749
Boehringer Ingelheim Canada Ltd.ltee32$26,806
Sekisui Diagnostics LLC4$26,455
Ferring Pharmaceuticals AS5$21,090
AbbVie(2 entities)134$18,491
Tolmar, Inc.8$17,032
Gilead9$16,515
Siemens Medical Solutions USA, Inc.8$7,990
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Novo Nordisk235$3,408
Lexicon Pharmaceuticals, Inc.2$2,811
Amgen(2 entities)95$1,585
Boehringer Ingelheim International GmbH18$1,393
Lilly USA, LLC53$917
Astellas Pharma US Inc30$693
GSK31$482
Bayer24$431
Sanofi-aventis U.S. LLC16$280
Johnson & Johnson16$276
Amarin Pharma, Inc.10$185
Takeda Pharmaceuticals U.S.A., Inc.21$169
Stryker2$138
Kowa Pharmaceuticals America, Inc.10$138
Teva Pharmaceuticals USA, Inc.10$135
Idorsia Pharmaceuticals US Inc4$133
Mannkind Corporation2$119
Axsome Therapeutics, Inc.4$97
Baudax Bio Inc.1$96
Biogen5$89
Paratek Pharmaceuticals, Inc.4$83
E.r. Squibb & Sons, L.L.C.5$74
Sumitomo Pharma America, Inc.3$71
Phathom Pharmaceuticals, Inc.1$67
Grifols USA, LLC3$56
Daiichi Sankyo Inc.3$49
Regeneron Healthcare Solutions, Inc.3$48
Abbott3$48
Exact Sciences2$48
Corcept Therapeutics2$46
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$46
Esperion Therapeutics, Inc.3$46
Antares Pharma, Inc.3$40
Biohaven Pharmaceutical Holding Company Ltd.2$37
Janssen Scientific Affairs, LLC1$35
Shield Therapeutics Inc2$33

How this compares

$6,760,249 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$1,802,222
Medicare patients
1,780
Services billed
48,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Deland

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →